Apellis Pharmaceuticals (APLS) EBITDA (2020 - 2025)
Historic EBITDA for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $215.9 million.
- Apellis Pharmaceuticals' EBITDA rose 47726.79% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 11813.26%. This contributed to the annual value of -$197.6 million for FY2024, which is 6279.96% up from last year.
- As of Q3 2025, Apellis Pharmaceuticals' EBITDA stood at $215.9 million, which was up 47726.79% from -$41.7 million recorded in Q2 2025.
- In the past 5 years, Apellis Pharmaceuticals' EBITDA ranged from a high of $215.9 million in Q3 2025 and a low of -$219.4 million during Q2 2021
- Its 5-year average for EBITDA is -$107.7 million, with a median of -$138.9 million in 2022.
- Per our database at Business Quant, Apellis Pharmaceuticals' EBITDA crashed by 28523.16% in 2021 and then skyrocketed by 47726.79% in 2025.
- Quarter analysis of 5 years shows Apellis Pharmaceuticals' EBITDA stood at -$148.0 million in 2021, then decreased by 10.69% to -$163.8 million in 2022, then soared by 44.43% to -$91.1 million in 2023, then skyrocketed by 59.89% to -$36.5 million in 2024, then surged by 691.12% to $215.9 million in 2025.
- Its last three reported values are $215.9 million in Q3 2025, -$41.7 million for Q2 2025, and -$92.0 million during Q1 2025.